Polarized HLA Class I Expression on Renal Tubules Hinders the Detection of Donor-Specific Urinary Extracellular Vesicles
Liang Wu,Martijn van Heugten,Thierry van den Bosch,Hans Duimel,Carmen López-Iglesias,Dennis Hesselink,Carla Baan,Karin Boer
DOI: https://doi.org/10.2147/ijn.s446525
IF: 7.033
2024-04-12
International Journal of Nanomedicine
Abstract:Liang Wu, 1, 2 Martijn H van Heugten, 3 Thierry PP van den Bosch, 4 Hans Duimel, 5 Carmen López-Iglesias, 5 Dennis A Hesselink, 2 Carla C Baan, 2 Karin Boer 2 1 Department of Nephrology, the First Affiliated Hospital of Shaoyang University, Shaoyang, Hunan, People's Republic of China; 2 Erasmus MC Transplant Institute, University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam, the Netherlands; 3 University Medical Center Rotterdam, Department of Internal Medicine, Division of Nephrology and Transplantation, Rotterdam, the Netherlands; 4 Department of Pathology, University Medical Center Rotterdam, Rotterdam, the Netherlands; 5 The Microscopy CORE Laboratory at the Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands Correspondence: Liang Wu, Erasmus MC Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam Erasmus MC, Room No. Na-514, Doctor Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands, Tel +31 0622145029, Email Purpose: Kidney transplantation is the optimal treatment for patients with end-stage kidney disease. Donor-specific urinary extracellular vesicles (uEVs) hold potential as biomarkers for assessing allograft status. We aimed to develop a method for identifying donor-specific uEVs based on human leukocyte antigen (HLA) mismatching with the kidney transplant recipients (KTRs). Patients and Methods: Urine and plasma were obtained from HLA-A2+ donors and HLA-A2- KTRs pre-transplant. CD9 (tetraspanin, EV marker) and HLA-A2 double-positive (CD9+ HLA-A2+) EVs were quantified using isolation-free imaging flow cytometry (IFCM). Healthy individuals' urine was used to investigate CD9+ HLA-class-I+ uEV quantification using IFCM, time-resolved fluoroimmunoassay (TR-FIA), and immunogold staining cryo-electron microscopy (cryo-EM). Culture-derived CD9+ HLA-class-I+ EVs were spiked into the urine to investigate urine matrix effects on uEV HLA detection. Deceased donor kidneys and peritumoral kidney tissue were used for HLA class I detection with histochemistry. Results: The concentrations of CD9+ HLA-A2+ EVs in both donor and recipient urine approached the negative (detergent-treated) control levels for IFCM and were significantly lower than those observed in donor plasma. In parallel, universal HLA class I+ uEVs were similarly undetectable in the urine and uEV isolates compared with plasma, as verified by IFCM, TR-FIA, and cryogenic electron microscopy. Culture supernatant containing HLA class I+ vesicles from B, T, and human proximal tubule cells were spiked into the urine, and these EVs remained stable at 37°C for 8 hours. Immunohistochemistry revealed that HLA class I was predominantly expressed on the basolateral side of renal tubules, with limited expression on their urine/apical side. Conclusion: The detection of donor-specific uEVs is hindered by the limited release of HLA class I+ EVs from the kidney into the urine, primarily due to the polarized HLA class I expression on renal tubules. Identifying donor-specific uEVs requires further advancements in recognizing transplant-specific uEVs and urine-associated markers. Keywords: kidney transplantation, donor-specific biomarker, HLA, extracellular vesicles, human urine, renal tubule Kidney transplantation is the optimal treatment for patients with end-stage kidney disease. A percutaneous biopsy of the transplanted kidney is the gold standard for investigating the etiology of kidney dysfunction following transplantation. 1 However, this invasive diagnostic procedure is confined by various limitations, including patient discomfort, high costs, and sampling bias. 2 Moreover, the reliance on skilled professionals and the need for a hospital setting, primarily for ultrasound guidance, further restrict its accessibility and convenience. 3,4 For these reasons, minimally invasive biomarkers to monitor transplant organ function are sought after. Such a "liquid biopsy" may reflect the integrity of the graft without the limitations of a biopsy. 2,5,6 Extracellular vesicles (EVs) are phospholipid bilayer particles of approximately 50 to 500 nm. EVs are released by all mammalian cells and contain tissue-derived protein or RNA. 7 EVs also convey parent-cell-derived surface molecules and cargo and are involved in cell-to-cell communication. 8,9 Tetraspanins such as CD9 and CD63 are generally expressed membrane proteins in major EV subpopulations and are often used for EV recognition. 7 In immunity, EVs serve as mediators of immun -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology